​
​

Galectin Therapeutics Ownership | Who Owns Galectin Therapeutics?

OverviewRevenueFinancialsChart

Galectin Therapeutics Ownership Summary

Galectin Therapeutics is owned by 15.36% institutional investors, 30.96% insiders, and 53.69% retail investors. Vanguard group is the largest institutional shareholder, holding 3.41% of GALT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.00% of its assets in Galectin Therapeutics shares.

GALT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockGalectin Therapeutics15.36%30.96%53.69%
SectorHealthcare Stocks 47.25%8.01%44.75%
IndustryBiotech Stocks 45.35%7.81%46.83%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.25M2.00%-
Vanguard Institutional Extnd Mkt Idx Tr670.16K1.08%-
iShares Russell 2000 ETF372.10K0.60%-840.00
Fidelity Extended Market Index285.36K0.46%18.40K
Fidelity Small Cap Index198.84K0.32%-673.00
iShares Russell 2000 Growth ETF107.35K0.17%-
Vanguard Russell 2000 ETF92.75K0.15%-578.00
BlackRock Extended Equity Market K92.01K0.15%-39.00
Fidelity Total Market Index81.96K0.13%-201.00
iShares Russell 2000 Value ETF73.87K0.12%-

Recent Insider Transactions

DateNameRoleActivityValue
Oct 23, 2024ELDRED KARY-Buy$1.30K
Oct 17, 2024FREEMAN KEVIN D-Buy$3.43K
Oct 16, 2024FREEMAN KEVIN D-Buy$13.50K
Oct 16, 2024FREEMAN KEVIN D-Buy$13.50K
Aug 23, 2024Zordani Richard A. Jr.-Buy$2.30K

Insider Transactions Trends

DateBuySell
2024 Q44-
2024 Q34-
2024 Q242
2024 Q12-
2023 Q4--

GALT Ownership FAQ

Who Owns Galectin Therapeutics?

Galectin Therapeutics shareholders are primarily institutional investors at 15.36%, followed by 30.96% insiders and 53.68% retail investors. The average institutional ownership in Galectin Therapeutics's industry, Biotech Stocks , is 45.35%, which Galectin Therapeutics falls below.

Who owns the most shares of Galectin Therapeutics?

Galectin Therapeutics’s largest shareholders are Vanguard group (2.12M shares, 3.41%), Blackrock (1.56M shares, 2.52%), and Advisor group (1.13M shares, 1.82%). Together, they hold 7.75% of Galectin Therapeutics’s total shares outstanding.

Does Blackrock own Galectin Therapeutics?

Yes, BlackRock owns 2.52% of Galectin Therapeutics, totaling 1.56M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.53M$. In the last quarter, BlackRock increased its holdings by 851.14K shares, a 119.44% change.

Who is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested?

Solutions 4 wealth is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.18% of its assets in 36.08K Galectin Therapeutics shares, valued at 81.55K$.

Who is the top mutual fund holder of Galectin Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Galectin Therapeutics shares, with 2.00% of its total shares outstanding invested in 1.25M Galectin Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools